2. Signaling Pathways
  3. Immunology/Inflammation
  4. ALCAM/CD166

ALCAM/CD166

Activated Leukocyte Cell Adhesion Molecule

ALCAM (CD166), a cell surface glycoprotein, is a cell adhesion molecule of the immunoglobulin superfamily. ALCAM is expressed by various cell types, such as leukocytes and endothelial cells (ECs). ALCAM can bind to the T cell-expressed scavenger receptor CD6, endothelial L1CAM, and galectin-8. ALCAM regulates diverse pathophysiological processes, including T cell activation, leukocyte trafficking, and angiogenesis. ALCAM is a prognostic marker of cancers. ALCAM promotes tumor growth by controlling cell proliferation, adhesion, migration and invasion[1][2].

ALCAM/CD166 Related Products (2):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P99788
    Praluzatamab
    		Inhibitor 99.98%
    Praluzatamab is a monoclonal antibody targeting the activated leukocyte cell adhesion molecule (ALCAM/CD116). Praluzatamab can be used to synthesize Praluzatamab ravtansine (antibody-drug conjugates). Praluzatamab can be used for research of cancers.
    Praluzatamab
  • HY-P991532
    AT002
    		Inhibitor
    AT002 (CBAS-173, EJ212/007-Cl2-5) is a recombinant human IgG1 monoclonal antibody. AT002 targets the cell surface protein activated leukocyte adhesion molecule (ALCAM)/CD166. AT002 can be used in the research of cancer, autoimmune diseases and inflammatory diseases.
    AT002